The announcement of a $35 per month out-of-pocket cap for insulin for some individuals with Medicare is a real victory for the American Diabetes Association and for people with diabetes, said Robert Gabbay, MD, PhD, chief medical and scientific officer of the American Diabetes Association.
The announcement of a $35 per month out-of-pocket cap for insulin for some individuals with Medicare is a real victory for the American Diabetes Association and for people with diabetes, said Robert Gabbay, MD, PhD, chief medical and scientific officer of the American Diabetes Association.
Transcript:
How will Medicare's $35 per month out-of-pocket cap for insulin affect pricing policy for other people who rely on insulin?
For individuals that have the appropriate Medicare plans, it will significantly reduce the cost of insulin, and we're very excited about that. That's a real victory for the ADA and most importantly for people with diabetes. What we hope is that commercial payers and others will follow suit and be able to adopt similar programs. Some have. Again, this has been a wonderful, private-public partnership fostered by ADA's advocacy to reach this point. We hope to be able to extend this to all people that require insulin.
You are well known for implementing the patient-centered medical home and the medical neighborhood. How will you bring this experience to others in your new role at ADA?
Within the science and medicine portion of the ADA, where we really engage the wide breadth of professionals focused on diabetes, the plan will be, and the hope, of course, most people with diabetes are cared for by primary care providers. To be able to reach out to that constituency group, and engage them in ways to be able to improve care, will really have an opportunity to have a dramatic impact. One of the ways that ADA has been doing that, and we'll be launching a larger program that you'll hear about in the coming weeks, is around reducing therapeutic inertia that will leverage the patient-centered medical home and the neighborhood to improve the outcomes once again for people with diabetes.
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More